BI-3406 Size:10mg solid 3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

and bioavailabilities (F%) of 100 and 80%

Int J Mol Med

30 min) significantly suppresses the expression of FN and α-SMA

122 μM and 0

BI-3406 Size:10mg solid 3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrileBI 3406 is Potent & Selective SOS1:: KRAS Inhibitor (IC50=5 nM), which Opens a New Approach for Treating KRAS Driven Tumours. BI 3406 selectively binds to SOS1 and blocks the interaction with KRAS, irrespective of the KRAS mutation. BI 3406 causes RAS GTP and pERK reduction and inhibits cell growth of KRAS mutated cell lines, carrying most of the typical KRAS mutations (i. e. G12D, G12V, G13D and others). BI 3406, when administered orally to tumour